Aims Two open studies in healthy volunteers were conducted to determine the absolute bioavailability and metabolic disposition of zolmitriptan (311C90), a novel 5HT 1D agonist for the acute treatment of migraine. Methods After an initial test i.v. infusion, bioavailabilty was assessed by comparison of AUC after an i.v. infusion (3.5 mg ) and an oral tablet (10 mg), in six men and six women using a randomised, crossover design. Disposition was studied by administration of a 25 mg capsule, labelled with 100 mCi [ 14 C]-zolmitriptan, to five men and one woman on a single occasion. Results Zolmitriptan was well tolerated by both i.v. and oral routes. Adverse events were mostly mild, consistent with earlier studies and characteristic of this class of drug. Reports were similar in nature and number after both oral and iv dosing. Mean±s.d. oral bioavailability was 0.49±0.24 (0.38±0.16 in men and 0.60±0.28 in women). After oral dosing, C max and AUC values in women were approximately double those in men. Relative to zolmitriptan concentrations, metabolite concentrations were higher after oral dosing than after i.v., and higher in men compared with women. Half-life was significantly longer after oral dosing (mean 22%, 95% CI 6-35%). Mean±s.d. values for CL, V z and t 1/2,z after i.v. dosing (all subjects) were 8.7±1.7 ml min −1 kg −1 , 122±32 l and 2.30±0.59 h respectively. Following administration of 25 mg [ 14 C]-zolmitriptan, 91.5% of the dose was recovered in 7 days, 64.4±6.5% in urine and 27.1±6.0% in faeces. Less than 10% was recovered unchanged in urine, with 31.1±6.4% recovered as the inactive indole acetic acid metabolite. Most of the faecal material was unchanged zolmitriptan, representing unabsorbed drug. Plasma concentrations of [ 14 C] were slightly higher than those of the summed concentrations of known analytes zolmitriptan, the active N-desmethyl metabolite (183C91), the inactive N-oxide (1652W92) and indole acetic acid (2161W92) metabolites, which accounted for 86% of total plasma radioactivity. No other significant metabilites were detected in plasma. Some minor additional metabolites were detected in urine, none of which contributed more than 5% of the dose. Conclusions The data suggest that zolmitriptan undergoes first-pass metabolism and this is more extensive in men than in women. Zolmitriptan has suitable bioavailabilty for an acute oral migraine treatment and there are no significant unidentified metabolites in man.
to inhibit release of the neuropeptides (CGRP and substance Introduction P) from perivascular trigeminal sensory neurones [2, 3] . 5HT 1D receptors have also been shown to modulate Zolmitriptan (311C90, (S)-4[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl ]methyl-2-oxazolidinone) is a potent and nociceptive input at the level of the trigeminal nucleus caudalis, suggesting that central sites may represent an highly selective 5HT 1D receptor agonist in development for the acute treatment of migraine [1] . Action on '5HT 1D -additional target for migraine treatment [4] . In animal models, zolmitriptan has been shown to act at these central like' receptors present in the cranial circulation is thought sites in addition to its peripheral vascular effects [5] and in this way differs from sumatriptan which does not appear to placebo-controlled studies, zolmitriptan was effective in Consumption of caffeine-containing beverages was not allowed on any of the study days and volunteers were fasted 62-81% of migraine patients following oral doses of between 2.5 and 25 mg [7] . Zolmitriptan is well absorbed with doseovernight before each study day. On the first study occasion (test-dose), subjects received a 2.5 mg dose of zolmitriptan, independent kinetics and is extensively metabolized [8] . The metabolites hitherto identified in human plasma and urine diluted in 250 ml normal saline, given by continuous intravenous infusion using an IVAC pump over a 2 h period. are the same as those seen in the rat and dog, namely the N-desmethyl metabolite (183C91) which has 5HT 1D agonist A group mean AUC was calculated and compared with data from a previous administration of oral zolmitriptan to activity and the inactive N-oxide (1652W92) and indole acetic acid (2161W92) metabolites. Oral bioavailability was volunteers [8] . It was estimated that an i.v. dose of 3.5 mg given over 4 h would result in a similar plasma profile to an estimated to be 41% and 79% in the rat and dog respectively. We now report the results of studies to assess the absolute oral 10 mg dose. Thus, on the second and third occasions, subjects were randomised to receive a single zolmitriptan oral bioavailability of zolmitriptan using intravenous and oral zolmitriptan and its disposition using [
14 C]-zolmitriptan in 10 mg tablet or a 3.5 mg i.v. infusion. The three study occasions were separated by a minimum interval of 1 week. healthy volunteers.
Blood samples were taken via an intravenous cannula predose and then at 0.25, 0. known metabolites by a specific h.p.l.c. assay. on each of three study occasions. The study comprised two parts; a first 'test-dose' occasion was to establish the tolerability to intravenous zolmitriptan and to determine the Clinical investigations In both studies, blood pressure and heart rate were measured at intervals in a supine position, pharmacokinetics of zolmitriptan and its metabolites when administered by this route. In the second crossover part, the using an automatic oscillometric device (Hewlett Packard 70354A). For the first 4 h post-dose, volunteers were same 12 subjects were randomized to receive a single zolmitriptan 10 mg oral tablet on one occasion and on confined to their beds and then rested for 10 min before each subsequent measurement. Any adverse experiences another occasion, an intravenous dose predicted to give mean plasma zolmitriptan concentrations approximately reported spontaneously or observed by the investigators were recorded. ECG was monitored continuously for 24 h equivalent to a 10 mg oral dose. The data obtained were used to estimate the absolute bioavailability of the zolmitripby bedside monitor or telemetry and a central arrhythmia detection system with alarm (Hewlett Packard HP78560A). tan 10 mg tablet. Using data from a previous study [8] , it was estimated that a bioavailability of 100% would have a In addition, ECG was recorded by Holter monitoring (Hertford Medical, Hertford, UK). Detection of arrhythmias confidence interval (CI) of approximately ±10%. To take into account the possibility that pharmacokinetics would and quantitative analysis of ST segments was performed using the Reynolds Medical 'Professional' model P53 differ between the sexes, the randomisation code was stratified, such that on each of the crossover occasions half analyser. In addition, plasma biochemistry and full blood counts were performed both before and after each dosing the subjects of each sex would would receive the 10 mg tablet and half the 3.5 mg i.v. dose.
occasion and inspected for abnormalities or trends.
Plasma and urine assays for zolmitriptan and metabolites scintillation vials and mixed with scintillator cocktail (Hionic Fluor). Triplicate aliquots of blood and faecal homogenates Plasma and urine samples were analysed for the parent compound zolmitriptan and its major metabolites by solid were measured for radioactivity following combustion either in a Packard Tricarb D306 or D307 sample oxidiser. phase extraction, followed by a validated, specific, reversephase h.p.l.c. method with fluorescence detection. The quantifiable ranges were between 2-150 ng ml −1 and 100-H.p.l.c. radioprofiling Urine and faecal samples containing sufficient radioactivity were analysed by an h.p.l.c. system 15000 ng ml −1 in plasma and urine respectively.
Plasma was separated by centrifugation of blood samples comprising a Waters 715 Ultra WISP autosampler, a Jasco 875-UV detector and an LDC/Milton Ray solvent delivery at 3000g for 10 min and stored at −20C°or below. Sample preparation was carried out using solid phase extraction on system. A Berthold radioactivity monitor (LB506 C-1) with a LB5035 pump to deliver liquid scintillator was used to C 18 Bond-Eluts from Anachem. Extraction cartridges were prewashed with 1 ml acetonitrile, 0.5 ml water and 1 ml monitor radioactivity in the h.p.l.c. element. Urine was filtered using a Millipore 0.22 mm non-sterile Ultrafree-Mc sodium formate buffer (pH 4.0). A 0.1 ml aliquot of plasma and 25 ml of internal standard (890W92; (4S)-4-[3-(1-methylcentrifuged filter unit or an Anotop 0.2 mm disposable syringe filter unit prior to radioactive component h.p.l.c. 4-piperidyl)-1H-indol-5-yl]2-oxazolidinthione) were applied to the cartridge and drawn through under low vacuum. The analysis. Weighed aliquots of selected faecal homogenates were extracted with methanol and centrifuged prior to cartridge was then washed with 1 ml sodium formate buffer, 0.75 ml water and 0.5 ml of 5% acetonitrile in water (v/v).
h.p.l.c. analysis. Separation of the analytes was achieved with a Zorbox Rx-C8 analytical column at ambient Elution of the analytes of interest from the cartridge was achieved by washing the cartridge with 0.3 ml of 30% temperature, using a binary gradient. The two mobile phases consisted of (A) 0.1% (v/v) formic acid in h.p.l.c. grade acetonitrile: 70% 0.01m di-ammonium hydrogen orthophosphate (pH 3.0) (v/v). This was then transferred to an water and (B) 0.1% (v/v) formic acid in acetonitrile. A flow rate of 1 ml min −1 was monitored with u.v. detection h.p.l.c. vial for injection. The system comprised a Zorbax TMS column (25 cm×4.6 mm id), a mobile phase of 15% at 230 nm. acetonitrile: 85% 0.01m di-ammonium hydrogen orthophosphate pH 3.0 (v/v) and an injection volume of 175 ml
Metabolite identification by liquid chromatography-mass spectrometry ( LC-MS)
A similar h.p.l.c. system to the above, with a 1 ml min −1 flow rate. Fluorescence detection was at 350 nm using a VG Multichrom data system. coupled to a Finnigan-MAT TSQ 700 mass spectrometer via a pneumatically assisted electrospray source, was used for The volume of each urine collection was determined and a 20 ml aliquot taken and frozen at −20°C or below until all LC-MS and LC-MS-MS metabolite identification. Argon was used as the collision gas during tandem mass assay. 0.4 ml of each urine sample was shaken for 10 min with 0.4 ml 1m formic acid and 10 ml chloroform. The spectrometry. sample was then centrifuged at 3000g for 10 min and 20 ml of the urine/formic mixture (equivalent to 10 ml of urine)
Pharmacokinetic and statistical analysis drawn through a Bond-Eluts cartridge prepared as described above. The cartridge was washed and eluted as above except
Absolute bioavailability study Non-compartmental pharmacokinetic parameters were determined for zolmitriptan and that 2% acetonitrile was used in washing and elution was with 0.06 ml 40% acetonitrile in 0.01m sodium dihydrogen its metabolites for all three treatments using EXCEL 4.0. The observed peak plasma concentration, C max and the time orthophosphate. The h.p.l.c. consisted of a Zorbax SIL column (8 cm×4 mm) and a guard cartridge followed by to reach the peak concentration, t max were taken directly from the plasma concentration-time profiles. The area under Supelcosil LC-ABZ (25 cm×4.6 mm) with a mobile phase of (A) 5% (v/v) acetonitrile in 0.04m soduim dihydrogen the plasma concentration-time curve was estimated by the trapezoidal rule up to the last measurable concentration orthophosphate and (B) 60% (v/v) acetonitrile in 0.04m sodium dihydrogen orthophosphate in the ratios 0 min: A= AUC(0, t) and extrapolated to infinity (AUC) by addition of C t /l z where l z is the first-order elimination rate constant, 100%, 10 min: A=80%, 15 min: A=0%, 25 min: A=100%.
A calibration curve for each analyte was constructed from obtained by log linear regression. The corresponding area under the first moment curve (AUMC) was calculated and the calibration sample included in the assay using the peak height ratio of analyte/internal standard. Sample peak height the mean residence time (MRT) was calculated from MRT=AUMC/AUC following oral zolmitriptan and from ratios were then calculated and concentrations determined from the appropriate standard curve. The standard curve AUMC/AUC-Infusion period/2 following intravenous zolmitriptan. The absolute bioavailability of oral zolmitriptan was a linear fit with a 1/concentration weighting. The assay precision and bias was less than 20% at the limit of was calculated from AUC po /AUC iv × Dose iv /Dose po . Elimination half-life (t D ,z ) was calculated as ln2/l Z . Clearance quantification and less than 15% at concentrations of 10 ng ml −1 and above in plasma and 200 ng ml −1 and above following intravenous administration (CL) was calculated as CL=Dose/AUC. Renal clearance (CL R ) was calculated as in urine.
CL R =Ae/AUC where Ae is the amount excreted in urine. Volume of distribution (V z ) was calculated as V z =CL/l z . Determination of radioactivity Total radioactivity in whole blood, plasma, urine and faecal samples was determined by Differences between the sexes for zolmitriptan pharmacokinetic parameters obtained from the 3.5 mg i.v. dose were liquid scintillation counting (LSC) using either a Beckman LS5801 or LC5000 CE liquid scintillation counter. Duplicate estimated and 95% CI calculated using analysis of variance. All data (except t max , Ae and MRT) were log-transformed aliquots of plasma and urine were weighed directly into
and 2161W92, were also estimated (and 95% CI neck. Such symptoms are characteristic of this class of drug [6] . There were more reports by women but the number calculated). The half-life and AUC m /AUC p data for zolmitriptan from the 3.5 mg i.v. dose and the 10 mg tablet and nature of reports were similar after both oral and i.v. dosing. No clinically significant changes in pulse, blood were compared using ANOVA.
pressure, ECG or clinical/laboratory parameters were observed in either study. Metabolic disposition study Pharmacokinetic parameters were calculated as described above for the absolute bioavailability study. C max and AUC determined for plasma levels of Pharmacokinetics radioactivity were expressed as nmol equivalents. The concentration of [ 14 C] in red blood cells was calculated as Absolute bioavailability After i.v. dosing, C max and AUC were higher in women than men with mean ratios of 79% C RBC =(C B -C P (1-Hct))/Hct, where C RBC is the red blood cell concentration, C B is the whole blood concentration, (95% CI 59-106%) and 77% (95% CI 56-105%) respectively. Weight adjusted clearance was only slightly higher in men C P is the plasma concentration and Hct is the haematocrit value. Percent recoveries of individual compounds and total than women after i.v. dosing (Table 1) suggesting that most, but not all, of the concentration difference was due to radioactivity in urine and faeces were calculated. differences in body weight. After dosing by the oral route, individual peak concentrations varied more widely than after Results iv and multiple peaks were observed, in common with earlier studies (Table 1, Figure 2 ). Mean C max values were All subjects enrolled completed the studies and there were no major protocol deviations. In the bioavailability study, similar after the 3.5 mg i.v. and 10 mg oral doses. AUC values were similar in men after the oral and i.v. dose but for females (n=6), mean age was 27 years (range 21-34 years), mean height was 169 cm (range 162-175 cm)
were over 50% higher in women after oral dosing. After oral dosing, C max and AUC values were much and mean weight was 65 kg (range 58-72 kg); for males (n=6) mean age was 33 years (range 25-38 years), mean lower in men with male5female ratio estimates of 61% (95% CI 35-107%) and 49% (95% CI 29-84%) respectively height was 177 cm (range 166-188 cm) and mean weight was 78 kg (range 61-95 kg). In the metabolic disposition (Tables 1 and 2 ). After oral dosing t D ,z was 2.94 h compared with 2.30 h (all subjects) after i.v. dosing (95% CI for ratio study (5M, 1F) ages ranged from 32-47 years, heights from 162-198 cm and weights from 59-89 kg.
106-135%). The mean absolute bioavailability of the 10 mg tablet was estimated at 49%. In females, this was 60% with All but one subject in each study reported at least one adverse experience. None was serious and most were mild values ranging from 32 to 110% and in males was 38% with individual values ranging from 21 to 62%. This difference females even after correction for body weight but this was not significant. Other parameters were similar between just failed to reach statistical significance.
Mean peak concentrations of 183C91, the pharmacologithe sexes. cally active N-desmethyl metabolite, were approximately two-fold higher after oral dosing than intravenous and were Disposition Although there was considerable intersubject variability, the shape of individual plasma profiles for 20% and 38% respectively of the peak concentrations of the parent following the 3.5 i.v. dose and 10 mg oral dose radioactivity, zolmitriptan and metabolites were similar (Figure 3 ). At all time points, plasma concentrations of [ 14 C] respectively (Table 1 ). Due to the low concentrations of 183C91 after i.v. dosing with zolmitriptan it was not were slightly higher than the summed concentration of known analytes (zolmitriptan, 183C91, 1652W92 and possible to determine the elimination rate constant in any subjects; consequently no pharmacokinetic parameters could 2161W92), these accounting for 76-98% of the radioactivity at each time point and 86% of total plasma radioactivity. be estimated. After oral dosing parameters could be estimated in nine subjects. Parameters were largely consistent between LC-MS analysis detected no further drug-related peaks. Half-life of radioactivity was similar to that for zolmitriptan. sexes although, relative to peak concentrations of zolmitriptan, peak concentrations of 183C91were higher in men.
Calculated red blood cell [ 14 C] concentrations were 27-56% of plasma [ 14 C] at all time points 1-6 h post-dose. Renal clearance was slightly higher after oral dosing than i.v. The t max and t D ,z were similar to the parent compound. By the end of the 7-day collection period, a mean±s.d. of 91.5±7.0% of the administered dose was recovered with Plasma concentrations of 1652W92, the inactive N-oxide metabolite, were generally too low to enable accurate 64.4±6.5% of the dose in urine and 27.1±6.0% in faeces. The majority of radioactivity, zolmitriptan and known determination of the elimination rate constant and other pharmacokinetic parameters. Relative to zolmitriptan peak metabolites were excreted in the first 24 h (Figure 4) . The relative excretion profiles were similar for all subjects. The concentrations, the mean peak concentrations of 1652W92 following the 10 mg oral dose were nearly twice those data indicate that mean (±s.d.) urinary recovery of zolmitriptan and known analytes accounted for 50.0±5.4% following 3.5 mg i.v. (23% and 15% of the parent respectively) with a trend for higher concentrations in males.
of the total administered dose, representing approximately 78% of the [ 14 C] in urine. A further six radiolabelled Similarly, peak concentrations of 2161W92, the inactive indole acetic acid, following 10 mg orally, were more than components, not corresponding to parent and its three major metabolites were detected in some urine samples by twice those seen after 3.5 mg i.v. (75% and 36% of the parent respectively) but, as with 183C91, there was little radiochromatographic h.p.l.c. analysis. The largest of these minor peaks, accounting for 3.8-5.1% of the dose, was evidence of any gender difference in plasma concentrations, resulting in higher metabolite ratios in men (Tables 1 and  identified by LC-MS as an intermediate metabolite, a methylamine metabolite of the indole acetic acid. A second 2). AUC was approximately three-fold larger after oral dosing with a mean (range) AUC m /AUC p of 1.05 peak was a probable oxidation product of a known primary amine derivative of zolmitriptan and accounted for 1-2.5% (0.44-2.14) compared with 0.52 (0.33-0.83) following the 3.5 mg infusion. Renal clearance was generally lower in of the administered dose. The remaining components were Table 2 Ratio estimates (Male5Female) and 95% confidence intervals for pharmacokinetic parameters for 311C90 and its metabolites, following an intravenous infusion of 3.5 mg and an oral dose of 10 mg 311C90. not detected by LC-MS due to their low concentrations of Discussion 1.7-3.9% (one peak) and 0.3-2.2% (remaining three peaks) of the radioactive dose.
Results of the two studies reported here agree with previous findings in humans that zolmitriptan is well absorbed and The majority of the radioactivity recovered in faeces was unchanged parent with the indole acetic acid the only other predominantly eliminated by metabolism after oral administration [8]. Mean peak plasma concentrations are higher detectable metabolite. than those previously reported which can be explained by differences in hepatic enzyme activity, or in the effects of zolmitriptan on liver blood flow. Although a peripheral the probable higher oral bioavailabilty in women as they were excluded from this previous study [8] . In common vasoconstrictor, zolmitriptan has been associated with increased liver blood flow in anaesthetised cats; such increases with previous findings, several volunteers exhibited multiplepeaks in their plasma profiles for zolmitriptan and metabolites may, in turn, increase its own metabolism [Dr D. Cambridge,
]. This is a reported property of oral sumatriptan [10] and is almost certainly an absorption phenomenon, rather However, the enzymes responsible for zolmitriptan metabolism remain unidentified, hence the full explanation of the than a result of enterohepatic recycling as it was not observed following the intravenous infusions and is observed reasons for the gender difference in first-pass metabolism remain unclear. All subjects were non-smokers and none in rats following oral but not i.v. administration.
The absolute bioavailability of zolmitriptan of 49% is consumed excessive quantities of alcohol, therefore these inducing agents are unlikely to explain the differences. consistent with preclinical values and confirms that, in humans, the bioavailability is over three times greater than Overall, however, there was only a small difference in the range of concentrations in women compared with men after that of sumatriptan [11] , which undergoes extensive presystemic metabolism in the gut wall and/or liver. The less oral zolmitriptan and it is unlikely the potential gender differences in pharmacokinetics will translate to differences than complete oral bioavailability of zolmitriptan is due to a combination of first-pass metabolism and incomplete absorpin treatment doses. All three major metabolites had mean half-lives similar to tion with over 20% of the oral dose present as unchanged drug in the faeces. The gender effect on the plasma that of parent. In the continued presence of zolmitriptan, these values cannot be assumed to be the true elimination concentrations of zolmitriptan, even allowing for differences in body weight and distribution volume, was unexpected.
half-lives; their similarity to parent drug indicating formation rate limited elimination. The significantly longer half-life These differences are probably mostly due to the higher bioavailability in women. However, with the large betweenafter oral dosing compared with i.v. suggests that the kinetics of oral zolmitriptan may also be absorption rate limited. The subject variability and small sample size in this study, the estimate of the difference in bioavailability for men compared indole acetic acid was found to be the most abundant metabolite, with significantly higher plasma concentrations with women must be treated with some caution. Higher bioavailability could be due to either better absorption or and an AUC value twice that of the parent compound after the 25 mg dose. A previous study reported the AUC ratio reduced first-pass metabolism. The former is unlikely since gender-specific absorption differences are unusual and total of this metabolite to be 60% [8] ; this earlier estimate is likely to be less accurate due to the limit of quantification urinary recovery of zolmitriptan and metabolites was similar in men and women. The evidence suggests that a difference being improved ten-fold before the studies described here were conducted. This analogue is also the major metabolite in first-pass metabolism is likely; the higher metabolite ratios after oral as compared to iv dosing suggest that the drug does of sumatriptan with six-seven fold higher plasma concentrations and formation limited kinetics [13] . Renal clearance undergo first-pass metabolism and the inter-subject variability in plasma concentrations following oral dosing is greater than represents 20% of total clearance and is much greater than glomerular filtration rate, indicating active renal tubular after intravenous dosing, typical of compounds subject to high first-pass clearance [12] . In addition, the higher metabsecretion.
Values in excess of 60% of drug-related material in urine olite ratios in men indicates that metabolism of the drug is more extensive; reduction in metabolite elimination is indicate at least this percentage is absorbed from the gastrointestinal tract. Faecal recovery of zolmitriptan was mainly unlikely in men since CL R was actually higher. Furthermore, systemic clearance, which is mostly metabolic, was also as unchanged parent, suggesting that this amount of drug remains unabsorbed. higher in men than women although the differences were small. It might be expected that systemic metabolic clearance
In conclusion, mean oral bioavailability of a 10 mg dose of zolmitriptan is 49% and is probably higher in women would be higher in men if first-pass metabolism were more extensive.
than men, with less extensive first-pass metabolism. Its major route of elimination is metabolic with over 60% of the oral Possible explanations for the gender difference include 7 Ferrari MD. The clinical effectiveness of 311C90 in the acute dose recovered in urine, the majority as the indole acetic treatment of migraine. Eur Neurol 1996; 36(suppl 2): 4-7. acid analogue. These studies have confirmed that zolmitrip- 
